Eastern European Breast Cancer Update

Eastern European Breast Cancer Update
8-10 April 2010 • Prague, Czech Republic

Meeting Overview

prIME Oncology’s Eastern European Breast Cancer Update is a 1.5-day educational activity for Eastern European and Russian delegates. The meeting will focus on updates in breast cancer management and will include highlights from the 2009 San Antonio Breast Cancer Symposium (SABCS), the 4th International Breast Cancer Conference (IBCC4), and the 7th European Breast Cancer Conference (EBCC7).

The format of the meeting features standard didactic presentations, interactive clinical cases, and clinical opinion poll questions. “Ask the Experts” sessions will give attendees the opportunity to pose questions to international breast cancer experts. This approach will allow for a highly interactive environment in which physicians can update their knowledge on breast cancer therapies and enhance decision-making capabilities in this area.

Location
Andel’s Hotel Stroupeznickeho 21 Prague, Czech Republic Tel: +420 296 889 688

Faculty

Co-Chairs
Day 1:
John Crown, MD
St Vincent’s Hospital
Dublin, Ireland

Vladimir Semiglazov, MD
NN Petrov Research Institute of Oncology
St Petersburg, Russia

Day 2:
Sunil Verma, MD
Toronto Sunnybrook Regional Cancer Center
Toronto, Ontario, Canada

Faculty
Alessandra Gennari MD, PhD
Galliera Hospital
Genoa, Italy

John Pippen, MD
US Oncology
Baylor Sammons Cancer Center
Dallas, Texas, United States

N. N. Semenov, MD
Blokhin Cancer Research Center
Moscow, Russia

Marina Stenina, MD
Blokhin Cancer Research Center
Moscow, Russia

Agenda

Thursday, 8 April 2010 – Arrivals

Friday, 9 April 2010
09.00		Welcome and demographics John Crown, MD Vladimir Semiglazov, MD
09.15		Clinical opinion poll question
09.25		The role of nonanthracycline-based chemotherapy regimens in the adjuvant setting Marina Stenina, MD Faculty commentary
09.55		Clinical opinion poll question
10.05		Can the benefits of adjuvant systemic therapy for HER2-negative breast cancer be further improved? John Crown, MD Faculty commentary
10.35		Ask the experts
10.55		Break
11.15		Clinical opinion poll question
11.25		Breast cancer molecular profiling as a guide to treatment planning Sunil Verma, MD Commentary: Alessandra Gennari, MD, PhD
12.05		Clinical opinion poll question
12.15		Triple-negative breast cancer: Current therapeutic strategies and future directions John Pippen, MD Faculty commentary
12.45		Ask the experts
13.00		Lunch
14.00		Clinical opinion poll question
14.10		Strategies for improving outcomes in HER2-negative metastatic breast cancer Alessandra Gennari, MD, PhD Faculty commentary
14.40		Clinical opinion poll question
14.50		HER2-amplified metastatic breast cancer: Optimal management of disease progression during trastuzumab therapy Sunil Verma, MD Faculty commentary
15.20		Ask the experts
15.40		Concluding remarks and review of Day 2 agenda John Crown, MD Vladimir Semiglazov, MD

Saturday, 10 April 2010
09.00		Economic realities: Their impact on practice guidelines in oncology Vladimir Semiglazov, MD Faculty commentary
09.30		Interactive Clinical Case #1 Early breast cancer: Optimizing outcomes of adjuvant therapy Sunil Verma, MD
10.00		Panel discussion
10.10		Interactive Clinical Case #2 Management of locally advanced, endocrine-responsive breast cancer Parts I & II: Vladimir Semiglazov, MD Part III & IV: N. N. Semenov, MD
10.40		Panel discussion
10.50		Ask the experts
11.10		Break
11.30		Interactive Clinical Case #3 Targeted therapy for HER2-overexpressing metastatic breast cancer Alessandra Gennari, MD, PhD
12.00		Panel discussion
12.10		Interactive Clinical Case #4 Current management of recurrent triple-negative breast cancer: What’s the best approach? John Pippen, MD
12.40		Panel discussion
12.50		Ask the experts
13.10		Concluding remarks Sunil Verma, MD

Learning Objectives

Upon completion of this educational activity, participants should be able to:

Analyze the role of anthracycline-based regimens in patients with early breast cancer, including optimal patient selection and management of side effects

Identify novel therapeutic agents that may be used in the adjuvant and neoadjuvant settings to further improve patient outcomes

Describe the role of molecular profiling in breast cancer, and discuss how these profiles guide choice of therapy

Analyze the latest clinical research on systemic therapy for patients with metastatic triple-negative breast cancer

Review the results of recent clinical trials focusing on the addition of anti-angiogenic therapy to standard treatment for metastatic breast cancer

Summarize emerging data for novel therapeutic agents that may be used in patients who have had disease progression following standard chemotherapy

Evaluate and select optimal treatment strategies for the management of HER2-positive breast cancer
Outline appropriate treatment options for the management of locally advanced, endocrine-responsive breast cancer
Identify the potential effects of economic limitations on current treatment guidelines for breast cancer